Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

Clinical evidence — proven platform Transcatheter Aortic Valve Implantation (TAVI)

DOWNLOAD SURTAVI 5-YEAR RESULTS (opens new window)

The Evolut TAVI System Proven Platform

The Evolut^TM TAVI System is built on a proven platform that provides industry-leading hemodynamics, advanced sealing and a low-profile delivery. The CoreValve^TM TAVI platform is the only TAVI platform currently on the market that demonstrates significantly better outcomes in all-cause mortality or stroke over surgery in high-risk patient at 3 years.¹

pdf SURTAVI 5-YEAR RESULTS (.pdf) (opens new window)

(opens new window)

COREVALVE U.S. PIVOTAL HIGH RISK TRIAL²

The CoreValve U.S. Pivotal High Risk Trial is a prospective, randomized, multicenter, noninferiority trial to compare the safety and efficacy of the Medtronic CoreValve system to SAVR in patients with symptomatic severe aortic stenosis at increased surgical risk.

Study Status/Duration: 3-year outcomes reported/5-year follow-up
Sample Size: N = 795 (TAVR = 391, SAVR = 359)
Devices: CoreValve TAV

Download STudy (opens new window)

(opens new window)
View Larger(opens new window)

The Medtronic TAVI supra-annular valve design contributes to industry-leading hemodynamics.

SEE INDUSTRY-LEADING HEMODYNAMIC DATA

Contact us

CLICK HERE (opens new window)

Lifeline cardiovascular technical support

rs.cstechsupport@medtronic.com

Medtronic Academy

View more clinical data and access procedural resources.

EDUCATION & RESOURCES

Find additional feature information, educational resources, and tools.

VISIT MEDTRONIC ACADEMY (opens new window)

Deeb, et al. (2015) presentation

Deeb GM, Reardon MJ, Chetcuti S, et al. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. June 7, 2016;67(22):2565-2574.